MBX MBX Biosciences, Inc.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

MBX Biosciences, Inc. (MBX) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Full-year 2025 financial results announced March 12, 2026
• Details and key figures contained in Exhibit 99.1 press release — primary source for revenue, cash, and pipeline spend data

Other MBX Biosciences, Inc. 8-K Filings

8-K Mar 9, 2026

8-K Feb 27, 2026

Get deeper insights on MBX Biosciences, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.